NCT02679729View on ClinicalTrials.gov

To Assess the Safety, Tolerability and Pharmacokinetics of AZD5634 Following Inhaled and Intravenous (IV)Dose Administration

PHASE1CompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

February 11, 2016

Primary Completion Date

October 24, 2016

Study Completion Date

October 24, 2016

Conditions
Cystic Fibrosis
Interventions
DRUG

AZD5634 for inhalation

Solution, citrate buffer, saline nebulizer solution; strength 0.1 - 5 mg/g; administered by jet nebulizer

DRUG

AZD5634 for infusion

Solution, citrate buffer, saline solution for infusion; strength 0.013 mg/mL

OTHER

Placebo

inactive substance

Trial Locations (2)

21225

Research Site, Baltimore

91206

Research Site, Glendale

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY